产品
编 号：F354528
分子式：C14H6N2O2S
分子量：266.27
分子式：C14H6N2O2S
分子量：266.27
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
结构图
CAS No: 4219-52-7
产品详情
生物活性：
NSC745885 an effective anti-tumor agent, shows selective toxicity against multiple?cancer?cell lines but not normal cells.?NSC745885 is an effective?down-regulator of EZH2 via proteasome-mediated degradation. NSC745885 provides possibilities for the study of advanced?bladder?and oral squamous cell carcinoma (OSCC) cancers.
体内研究：
NSC745885 (intraperitoneal injection; 2 mg/kg; once daily; 10 days) treatment significantly reduces tumor size when compared with the vehicle control, and exhibits a higher safety than doxorubicin.Animal Model:Eight-week-old NOD/SCID (NOD.CB17 Prkdcscid/J) mice
Dosage:2 mg/kg
Administration:Intraperitoneal injection; 2 mg/kg; once daily; 10 days
Result:Inhibited engrafted tumors growth in vivo.
体外研究：
NSC745885 (0.5-4 μM; 24, 48 or 72 hours) has a growth inhibitory or death-promoting effect on the SAS cells, it significantly decreases the densities of cultured cells when compared with untreated cells. The IC50 of NSC745885 is 0.85 μM after 72 hours’ treatment.NSC745885 (0.5-4 μM; 24hours) increases annexin V positive cells in a dose-dependent manner, and the differences appears as a dose-dependent manner.NSC745885 (0.5-2 μM; 24 or 48 hours) decreases XIAP protein levels and increases protein levels both as a dose-dependent manner in SAS cells.
NSC745885 an effective anti-tumor agent, shows selective toxicity against multiple?cancer?cell lines but not normal cells.?NSC745885 is an effective?down-regulator of EZH2 via proteasome-mediated degradation. NSC745885 provides possibilities for the study of advanced?bladder?and oral squamous cell carcinoma (OSCC) cancers.
体内研究：
NSC745885 (intraperitoneal injection; 2 mg/kg; once daily; 10 days) treatment significantly reduces tumor size when compared with the vehicle control, and exhibits a higher safety than doxorubicin.Animal Model:Eight-week-old NOD/SCID (NOD.CB17 Prkdcscid/J) mice
Dosage:2 mg/kg
Administration:Intraperitoneal injection; 2 mg/kg; once daily; 10 days
Result:Inhibited engrafted tumors growth in vivo.
体外研究：
NSC745885 (0.5-4 μM; 24, 48 or 72 hours) has a growth inhibitory or death-promoting effect on the SAS cells, it significantly decreases the densities of cultured cells when compared with untreated cells. The IC50 of NSC745885 is 0.85 μM after 72 hours’ treatment.NSC745885 (0.5-4 μM; 24hours) increases annexin V positive cells in a dose-dependent manner, and the differences appears as a dose-dependent manner.NSC745885 (0.5-2 μM; 24 or 48 hours) decreases XIAP protein levels and increases protein levels both as a dose-dependent manner in SAS cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备